Atrophic acne scars Acne scars Atrophic acne scars Picosecond laser Fractional laser therapy Microneedling Radiofrequency therapy Randomized controlled trial
Conditions
Interventions
1064 nm fractional picosecond laser treatment is performed on one side of the face for the treatment of atrophic acne scars. Participants receive 3 treatment sessions at 1 month intervals.,1064 nm fra
Experimental Device,Experimental Device
1064 nm fractional picosecond laser alone,1064 nm fractional picosecond laser combined with microneedle radiofrequency
Sponsors
Dhurakij Pundit University
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female adults aged 20 to 60 years 2. Moderate to severe atrophic acne scars with Goodman and Baron scale grade 3 or 4 3. Fitzpatrick skin types III to IV 4. Willing to participate in the study and able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women 2. Allergy to local anesthetics 3. Facial acne scar laser treatment within the past 6 months 4. Facial aesthetic procedures within the past 3 months 5. Active facial dermatitis, open wounds, or skin infection on the face 6. Immunodeficiency, including HIV infection 7. Oral retinoid use within the past 3 months 8. History of keloid or abnormal scar formation in the treatment area 9. Systemic diseases such as diabetes, thyroid disease, or cancer 10. Smoking 11. Psychiatric disorders 12. Any condition considered unsafe by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depressed scar volume Baseline, Week 12, Week 20 Antera 3D,Texture Baseline, Week 12, Week 20 Antera3D | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythema index Baseline, Week 12, Week 20 Mexameter,Melanin index Baseline, Week 12, Week 20 Mexameter,Quartile grading scale Baseline, Week 12, Week 20 by two dermatologists,Pain score 1st, 2nd, 3rd treatment Visual analog scale,Participant satisfaction Week 12, Week 20 Global Aesthetic Improvement Scale,Safety 1st, 2nd, 3rd treatment Adverse events | — |
Countries
Thailand
Contacts
Public ContactWanvisa Silpaiboonpanich
Dhurakij Pundit University
Outcome results
None listed